Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$145.61 USD
+1.20 (0.83%)
Updated Apr 22, 2024 11:55 AM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALNY 145.61 +1.20(0.83%)
Will ALNY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
Other News for ALNY
ProQR Therapeutics nominates Maier to board of directors
First Week of December 20th Options Trading For Alnylam Pharmaceuticals (ALNY)
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Wolfe upgrades Ionis to outperform, cites upcoming catalysts